Bruton J, Hanke T
Vaccines (Basel). 2025; 13(1).
PMID: 39852851
PMC: 11769474.
DOI: 10.3390/vaccines13010072.
Garutti M, Bruno R, Polesel J, Pizzichetta M, Puglisi F
Heliyon. 2024; 10(12):e32433.
PMID: 39183829
PMC: 11341338.
DOI: 10.1016/j.heliyon.2024.e32433.
Varey A, Li I, El Sharouni M, Simon J, Dedeilia A, Chng S
J Clin Oncol. 2024; 42(10):1169-1180.
PMID: 38315961
PMC: 11003510.
DOI: 10.1200/JCO.23.01020.
Tang H, Liu S, Luo X, Sun Y, Li X, Luo K
Front Immunol. 2023; 14:1150588.
PMID: 37090691
PMC: 10117669.
DOI: 10.3389/fimmu.2023.1150588.
Yunger S, Geiger B, Friedman N, Besser M, Adutler-Lieber S
Front Oncol. 2023; 13:1116328.
PMID: 36937426
PMC: 10020329.
DOI: 10.3389/fonc.2023.1116328.
Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies.
Stevenson V, Klahn S, LeRoith T, Huckle W
Front Vet Sci. 2023; 9:1046636.
PMID: 36686160
PMC: 9853198.
DOI: 10.3389/fvets.2022.1046636.
Molecular profiling of core immune-escape genes highlights LCK as an immune-related prognostic biomarker in melanoma.
Wang F, Zheng A, Zhang D, Zou T, Xiao M, Chen J
Front Immunol. 2022; 13:1024931.
PMID: 36341345
PMC: 9630653.
DOI: 10.3389/fimmu.2022.1024931.
HLA-DRB1: A new potential prognostic factor and therapeutic target of cutaneous melanoma and an indicator of tumor microenvironment remodeling.
Deng H, Chen Y, Wang J, An R
PLoS One. 2022; 17(9):e0274897.
PMID: 36129956
PMC: 9491554.
DOI: 10.1371/journal.pone.0274897.
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
Conway J, Rawson R, Lo S, Ahmed T, Vergara I, Gide T
J Immunother Cancer. 2022; 10(9).
PMID: 36096531
PMC: 9472156.
DOI: 10.1136/jitc-2022-004884.
is a Potential Immunosuppressive Factor in Skin Cutaneous Melanoma.
Zhang Q, Liu Y, Li J, Zeng S, Shen H, Han M
J Inflamm Res. 2022; 15:3065-3082.
PMID: 35637872
PMC: 9148213.
DOI: 10.2147/JIR.S362619.
Tumor-Infiltrating CD8+ T Cells Driven by the Immune Checkpoint-Associated Gene IDO1 Are Associated With Cervical Cancer Prognosis.
Zhang S, Wan J, Chen M, Cai D, Xu J, Chen Q
Front Oncol. 2021; 11:720447.
PMID: 34778035
PMC: 8578845.
DOI: 10.3389/fonc.2021.720447.
Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined using methylation analyses and its prognostic significance in resected gastric cancer.
Suh K, Kim J, Kim J, Sung J, Koh J, Kim K
PLoS One. 2021; 16(6):e0252480.
PMID: 34086741
PMC: 8177409.
DOI: 10.1371/journal.pone.0252480.
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients.
Lin Z, Meng X, Wen J, Corral J, Andreev D, Kachler K
Front Oncol. 2020; 10:596493.
PMID: 33344244
PMC: 7747763.
DOI: 10.3389/fonc.2020.596493.
Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment.
Diener J, Sommer L
Stem Cells Transl Med. 2020; 10(4):522-533.
PMID: 33258291
PMC: 7980219.
DOI: 10.1002/sctm.20-0351.
Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma.
Chou M, Illa-Bochaca I, Minxi B, Darvishian F, Johannet P, Moran U
Mod Pathol. 2020; 34(3):562-571.
PMID: 33005020
PMC: 7983061.
DOI: 10.1038/s41379-020-00686-6.
Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.
Kim S, Kim Y, Mustafa B, Kim M, Jeong G, Ahn S
Mod Pathol. 2020; 34(1):141-160.
PMID: 32709987
DOI: 10.1038/s41379-020-0633-x.
Biomarkers for immunotherapy for treatment of glioblastoma.
Lynes J, Nwankwo A, Sur H, Sanchez V, Sarpong K, Ariyo O
J Immunother Cancer. 2020; 8(1).
PMID: 32474411
PMC: 7264836.
DOI: 10.1136/jitc-2019-000348.
Systematic Multiomic Analysis of Gene Expression and Its Prognostic Value Through the Infiltration of Natural Killer (NK) Cells in Skin Cutaneous Melanoma.
Gil M, Kim K
J Clin Med. 2020; 9(5).
PMID: 32397120
PMC: 7291273.
DOI: 10.3390/jcm9051383.
Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment.
Kang T, Park J, Yang A, Park H, Lee S, Kim Y
Nat Commun. 2020; 11(1):1137.
PMID: 32111835
PMC: 7048819.
DOI: 10.1038/s41467-020-14821-z.
Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.
Keung E, Gershenwald J
J Natl Cancer Inst. 2020; 112(9):875-885.
PMID: 32061122
PMC: 7492771.
DOI: 10.1093/jnci/djaa012.